USP41 Inhibitors
Chemical inhibitors of USP41 employ a variety of mechanisms to impact its function within cellular processes. Trichostatin A, a known histone deacetylase inhibitor, increases the acetylation of histones, which can lead to alterations in chromatin structure. These alterations have downstream effects on DNA accessibility, which can inhibit the activity of USP41 by changing its interaction with chromatin or its substrate proteins. Chloroquine, by increasing the pH of lysosomes, interferes with degradation pathways such as autophagy. The disruption to these pathways can affect the turnover or recycling of USP41, ultimately leading to its functional inhibition. MG132 and Bortezomib are proteasome inhibitors that cause an accumulation of polyubiquitinated proteins. This saturation of the ubiquitin-proteasome system can hinder USP41's ability to bind and process its substrates, which is essential for its deubiquitination activity.
Other compounds, such as Eeyarestatin I, interfere with the endoplasmic reticulum-associated degradation pathway by inhibiting the p97 ATPase, leading to an accumulation of misfolded proteins in the ER which can affect the function of USP41. Lactacystin and Epoxomicin, both proteasome inhibitors, lead to the accumulation of ubiquitinated proteins. This accumulation can compete with or saturate USP41, reducing its effectiveness. Fulvestrant, by targeting estrogen receptors for proteasomal degradation, can indirectly inhibit USP41 by occupying the proteasome and limiting USP41's access to its substrates. Withaferin A binds to and inhibits proteasomal activity, which can cause an accumulation of proteins that normally require USP41 for deubiquitination. O-Phenanthroline, a metal ion chelator, although not directly inhibiting USP41, can affect various metal-dependent enzymes and cellular pathways that indirectly influence the activity of USP41. Finally, MLN4924 and Ginkgolic Acid act upstream by inhibiting NEDD8-activating enzyme and SUMO-activating enzyme respectively, affecting the turnover of ubiquitin chains and SUMOylation processes that can impact the functional role of USP41.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylase (HDAC), leading to an increase in acetylation of histones. This modification can alter the chromatin structure and subsequently affect the accessibility of DNA to USP41, inhibiting its function. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine accumulates in lysosomes, increasing their pH. This can impact the degradation pathways, such as autophagy, which could indirectly inhibit the function of USP41 by disrupting its turnover or recycling within the cell. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins. This can saturate the ubiquitin-proteasome system, potentially inhibiting USP41 by reducing its ability to bind to its substrates. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is another proteasome inhibitor that can indirectly inhibit USP41 by preventing the degradation of polyubiquitinated proteins, which may interfere with USP41's substrate recognition and deubiquitination activity. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Eeyarestatin I disrupts the endoplasmic reticulum-associated degradation (ERAD) pathway by inhibiting p97 ATPase, which can lead to the accumulation of misfolded proteins in the ER, potentially inhibiting the function of USP41. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome that can inhibit the degradation of ubiquitinated proteins, potentially leading to the functional inhibition of USP41 by substrate competition or saturation. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin irreversibly inhibits the proteasome, which can lead to the accumulation of ubiquitinated proteins. This might inhibit USP41 function by affecting the availability of ubiquitin or altering substrate interactions. | ||||||
ICI 182,780 | 129453-61-8 | sc-203435 sc-203435A | 1 mg 10 mg | $83.00 $187.00 | 34 | |
Fulvestrant degrades estrogen receptors by targeting them for proteasomal degradation. This might lead to competition with USP41 substrates, indirectly inhibiting USP41 activity by limiting its access to specific substrates. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A is known to covalently bind to and inhibit the proteasomal activity. This could lead to an indirect inhibition of USP41 by causing an accumulation of proteins that require USP41-mediated deubiquitination. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits the NEDD8-activating enzyme, which can decrease neddylation of cullin proteins and subsequently inhibit Cullin-RING ligases (CRLs). This may indirectly inhibit USP41 by altering ubiquitin chain turnover. | ||||||